Announcement no. 42/2022
Revised guidance for 2022 and preliminary results for Q2 2022
Össur expects organic growth of 4-6% for FY 2022 (previous 6-9%) and EBITDA margin before special items of 18-20% for FY 2022 (previous 20-21%). Currently, management estimates that organic sales growth and EBITDA margin before special items for FY 2022 will be around the middle of the new guidance range. Other guidance parameters remain unchanged.
Össur revises its financial guidance due to lower-than-expected sales and higher-than-expected supply chain cost for FY 2022. Although sales have been strong in many key markets in EMEA and APAC in the first half of the year, sales have been slower than expected in
Preliminary sales in Q2 2022 amounted to
Preliminary sales in 1H 2022 amounted to
Sveinn Sölvason, President and CEO, comments: "The preliminary results for the second quarter are disappointing. While sales remain strong in many of our key markets, we have experienced unforeseen events and supply chain challenges in the first half of the year which combined, affects our outlook for the full year. We are confident that our market position continues to be strong, and we expect continued organic growth in the remainder of the year."
Össur will release its Q2 2022 interim report as scheduled on
Conference call details
Össur will host a conference call today,
Link to webcast: Össur Webcast
To participate in the conference call, please click on this link: Össur Conference Call
Further information
Edda Lára Lúðvígsdóttir, Investor Relations Director, eludvigsdottir@ossur.com, +354 8444759
Össur press releases by e-mail
If you wish to receive Össur press releases by e-mail please register at http://www.ossur.com/investors
About Össur
Össur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that helps people live a Life Without Limitations. A recognized "Technology Pioneer" with a rich 50-year history, Össur focuses on improving people's mobility through the delivery of innovative technologies in Prosthetics and Bracing & Supports. Significant investment in research and development have led to over 2,000 patents, award-winning designs, successful clinical outcomes, and consistently strong market positions. Össur is signatory to the
https://news.cision.com/ossur-hf-/r/ossur-hf--revised-guidance-for-2022-and-preliminary-results-for-q2-2022,c3602664
https://mb.cision.com/Main/18404/3602664/1605476.pdf
(c) 2022 Cision. All rights reserved., source